Developer docs
API playgroundTry for free, no card

Search company profiles

Lyomark Pharma

Full company profile

uuid000v7gc

Namestring
Lyomark Pharma
Legal namestring
Lyomark Pharma GmbH
Websiteurl
lyomark.com
Company typeenum
Private
Founded yearint
1989
Descriptiontext

Lyomark Pharma GmbH is a privately held, German specialty pharmaceutical company founded in 1989 and headquartered in Oberhaching near Munich. It develops, manufactures, and distributes sterile pharmaceutical products — primarily lyophilized (freeze-dried) medicines and injectable solutions — for the international hospital market. Its portfolio is anchored in neonatology, with Alveofact (a bovine lung surfactant for treating respiratory distress syndrome in premature newborns, acquired from Boehringer Ingelheim in 2005), NeoKay (Vitamin K1 prophylaxis soft capsules, launched in Germany in 2014), and NEOFACT (an application aid for Less Invasive Surfactant Administration, launched in 2019). Beyond proprietary brands, Lyomark provides contract manufacturing from pilot to commercial scale, pharmaceutical active ingredient procurement with GMP-compliant storage, and regulatory services including eCTD dossier preparation, Product Quality Reviews and Periodic Safety Update Reports.

The company operates a dual go-to-market model: a direct sales organization in the German hospital market (established in 2006, selling since 2007) and an international licensing network of distribution partners that markets Lyomark products in more than 50 countries. It holds GMP and GDP certification and a manufacturing license from the Government of Upper Bavaria, with product approvals handled by the Federal Institute for Drugs and Medical Devices (BfArM). Its operating perimeter includes a majority stake in LYOCONTRACT GmbH (Ilsenburg, acquired August 2017), a licensed manufacturer of liquid and freeze-dried sterile products, and is grouped under shared ownership with sister company Bendalis GmbH (oncology medicines, founded 2005). Adjacent R&D is conducted through research partnerships with University Hospital Tübingen, University Medical Centre Hamburg-Eppendorf and University Hospital Bremen, and Lyomark holds a strategic development partnership with Aerogen Pharma for an inhalable surfactant form of Alveofact.

Lyomark generates revenue through four streams: contract manufacturing (professional services), pharmaceutical active ingredient supply (transactional), direct product sales in Germany (own brands), and international licensing royalties and co-distribution arrangements with foreign partners. As a privately held, self-described "mittelständisches Unternehmen" (medium-sized enterprise) with leadership transitions completed in 2021–2022 — Dr. Wolfgang Burger (from PharmaZell) and Dr. Dirk Hütten — Lyomark positions itself as a GMP-compliant, partner-oriented specialty manufacturer and licensor for the sterile hospital segment, with no disclosed institutional or private equity ownership.

Short descriptiontext

Lyomark Pharma GmbH is a privately held German specialty pharmaceutical company (founded 1989, Oberhaching near Munich) that develops, manufactures and licenses sterile lyophilized and injectable products — notably Alveofact, NeoKay and NEOFACT — for the international hospital market, serving neonatology, gastroenterology and oncology customers via direct German sales and licensing partners in 50+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOberhaching, Germany
HQ citystring
Oberhaching
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile pharmaceuticals manufacturing, lyophilized injectable products, neonatal lung surfactant, contract pharmaceutical manufacturing, hospital pharmaceutical supply
Industry4 codes
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Sterile Hospital Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Manufacturing Services
TypeProfessional Services
Description

Development of pharmaceutical formulations from pilot scale to commercial production, manufacture and packaging of lyophilised products and injectable solutions for pharmaceutical clients

lyomark.com
2Pharmaceutical Active Ingredients Supply
TypeTransaction Fee
Description

Procurement of all active pharmaceutical ingredients and excipients, qualification of active pharmaceutical ingredient suppliers, GMP-compliant storage and on-time delivery

lyomark.com
3Direct Product Sales (Germany)
TypeOne Time License
Description

Direct sales of own products in the German hospital market since 2007, including Alveofact, NeoKay, and related pharmaceutical products

lyomark.com
4International Licensing
TypeLicensing Royalties
Description

International licensing and collaborations with distribution partners for worldwide distribution of Lyomark Pharma products, including co-distribution arrangements for selected products

lyomark.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Alveofact
Description

Lung surfactant product for neonatal respiratory conditions

lyomark.com
+2 more records
Core offering1 text field

Lyomark Pharma develops, manufactures, and distributes lyophilized (freeze-dried) and liquid sterile pharmaceutical products for the international hospital market. Its product portfolio is anchored in neonatology (Alveofact lung surfactant, NeoKay Vitamin K1 capsules, NEOFACT application aid), with additional specialty pharmaceuticals in gastroenterology and oncology. Beyond its own brands, the company offers contract manufacturing, regulatory dossier services (eCTD, PQR, PSUR), and active pharmaceutical ingredient supply to other pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • NEOFACT showed 95% success rate in clinical feasibility study at University Hospital Tübingen
+1 more record
Product overview1 text field

Lyomark Pharma is a medium-sized pharmaceutical company specializing in sterile products for the hospital sector. The product portfolio centers on neonatology treatments including Alveofact® (bovine lung surfactant for respiratory distress syndrome), NEOFACT® (an innovative application aid for surfactant administration), and NeoKay® (Vitamin K1 prophylaxis). The company also provides contract manufacturing services for lyophilized and liquid sterile pharmaceuticals, pharmaceutical active ingredient procurement, regulatory services including PQR and PSUR creation, and international distribution partnerships. Products serve the hospital market across more than 50 countries.

Product and service6 records
1Alveofact®
CategorySterile Pharmaceuticals - Neonatal Lung Surfactant
Description

Bovine lung surfactant derived from bovine lung lavage, used for the treatment of respiratory distress syndrome (RDS) in premature newborns. It contains phospholipids and surfactant proteins SP-B and SP-C and is supplied in 108 mg and 54 mg dosage forms.

2NEOFACT® Application Aid
CategoryMedical Device - Neonatal Application Aid
Description

Medical device / application aid that enables simple and gentle surfactant administration without Magill forceps, designed to standardize the less invasive LISA technique in neonatal intensive care.

3NeoKay® 1 mg Soft Capsules
CategorySterile Pharmaceuticals - Neonatal Vitamin K Prophylaxis
Description

Vitamin K1 (phytomenadione) prophylaxis in 1 mg soft capsule form for newborns and infants, used to prevent bleeding, particularly cerebral haemorrhage, due to vitamin K-dependent clotting factors.

4Contract Manufacturing Services for Sterile Pharmaceuticals
CategoryContract Manufacturing Services
Description

Pharmaceutical formulation development from pilot scale to validated commercial batch size, plus manufacture and packaging of lyophilized products (freeze-dried medicines) and injectable solutions for the international hospital market, executed under GMP for pharmaceutical clients.

5Pharmaceutical Active Ingredients Supply Service
CategoryActive Pharmaceutical Ingredient Supply
Description

Sourcing, qualification, and supply of active pharmaceutical ingredients and excipients including provision of CEP and EDMF documentation, GMP-compliant storage, and on-time delivery for pharmaceutical manufacturers.

6Regulatory Services (eCTD, PQR, PSUR)
CategoryRegulatory Affairs Services
Description

Creation of Product Quality Reviews (PQR), Periodic Safety Update Reports (PSUR), and Regulatory Dossiers in eCTD format, together with database queries and ongoing support for approval processes for pharmaceutical clients.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-12-14
Description

Strategic partnership to develop an inhalable surfactant for the treatment of respiratory distress syndrome (RDS) in premature newborns, based on Lyomark's product Alveofact. Clinical studies were initiated with the new application form, with the first patients already recruited. The partnership aims to create a less invasive surfactant delivery method using Aerogen's aerosolized delivery technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-08-01
Description

Lyomark Pharma acquired a majority stake in LYOCONTRACT GmbH (based in Ilsenburg), which received its manufacturing licence in 2012 for production of liquid and freeze-dried sterile medicinal products. The plant was built to the latest standards and is among the most modern in its sector. Both companies remain privately owned and independently managed, with the goal of developing LYOCONTRACT into a leading contract manufacturer for sterile products.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sister company founded in 2006, specializing in the development and marketing of high-quality oncology medicines for the treatment of cancer. Both companies are privately owned and work together under shared ownership.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial partnership for NEOFACT feasibility study conducted at University Hospital Tübingen, where 20 preterm infants were administered surfactant using the NEOFACT application aid with 95% success rate.

5University Medical Centre Hamburg-Eppendorf
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership with Dr. Julian Trah's research group studying immunomodulatory effects of surfactant products (Alveofact, Curosurf) on NET formation in neutrophil granulocytes.

lyomark.com
6University Hospital Bremen
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership with Professor Dr. Dr. Ursula Mirastschijski investigating topical application of Alveofact for wound healing and scar formation, resulting in published Nature Magazine study.

lyomark.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Recipharm
TypeBroad incumbent
Description

European CDMO offering sterile fill-finish and lyophilization services; comparable to Lyomark's contract manufacturing business for pharmaceutical clients across formulation, scale-up, and commercial production.

TypeBroad incumbent
Description

Global pharma incumbent with a historic neonatal surfactant franchise (Survanta) following the Abbott and Allergan acquisitions; broader respiratory and hospital portfolio overlaps with Lyomark's specialty hospital focus.

TypeBroad incumbent
Description

Large global generics manufacturer with a substantial hospital sterile injectables business; a relevant comparability anchor for Lyomark's generic hospital injectables pipeline and international distribution model.

TypeDirect peer
Description

German-headquartered medical and pharmaceutical company with a large sterile injectables and hospital solutions portfolio; a closely comparable private German player in sterile hospital injectables.

TypeDirect peer
Description

German CDMO specializing in solid, semi-solid, and sterile liquid dosage forms; competes directly with Lyomark's contract manufacturing and lyophilization services for pharma clients.

TypeDirect peer
Description

Privately held Italian specialty pharma with Curosurf (poractant alfa), the global market-leading lung surfactant for neonatal RDS — directly competing with Lyomark's Alveofact in the same indication and customer base.

TypeBroad incumbent
Description

Global CDMO with sterile injectable manufacturing capabilities; competes for the same contract manufacturing and lyophilization work that Lyomark's LYOCONTRACT subsidiary targets.

TypeDirect peer
Description

Global manufacturer of generic injectable hospital products with a strong lyophilized injectables portfolio; directly comparable in hospital sterile injectables and contract manufacturing service offerings.

TypeRegional player
Description

German specialty and generics pharma with strong hospital presence in Europe; comparable in offering hospital sterile injectables and specialty products, though at significantly larger scale.

10Drägerwerk
TypeEmerging player
Description

German medical technology company with a strong neonatal care and respiratory product line (incubators, ventilators); comparable as a German specialty supplier into the same neonatal hospital customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lyomark Pharma

Sterile Hospital Pharmaceuticalslyomark.com

Lyomark Pharma GmbH is a privately held German specialty pharmaceutical company (founded 1989, Oberhaching near Munich) that develops, manufactures and licenses sterile lyophilized and injectable products — notably Alveofact, NeoKay and NEOFACT — for the international hospital market, serving neonatology, gastroenterology and oncology customers via direct German sales and licensing partners in 50+ countries.

What Lyomark Pharma does

Lyomark Pharma GmbH is a privately held, German specialty pharmaceutical company founded in 1989 and headquartered in Oberhaching near Munich. It develops, manufactures, and distributes sterile pharmaceutical products — primarily lyophilized (freeze-dried) medicines and injectable solutions — for the international hospital market. Its portfolio is anchored in neonatology, with Alveofact (a bovine lung surfactant for treating respiratory distress syndrome in premature newborns, acquired from Boehringer Ingelheim in 2005), NeoKay (Vitamin K1 prophylaxis soft capsules, launched in Germany in 2014), and NEOFACT (an application aid for Less Invasive Surfactant Administration, launched in 2019). Beyond proprietary brands, Lyomark provides contract manufacturing from pilot to commercial scale, pharmaceutical active ingredient procurement with GMP-compliant storage, and regulatory services including eCTD dossier preparation, Product Quality Reviews and Periodic Safety Update Reports.

The company operates a dual go-to-market model: a direct sales organization in the German hospital market (established in 2006, selling since 2007) and an international licensing network of distribution partners that markets Lyomark products in more than 50 countries. It holds GMP and GDP certification and a manufacturing license from the Government of Upper Bavaria, with product approvals handled by the Federal Institute for Drugs and Medical Devices (BfArM). Its operating perimeter includes a majority stake in LYOCONTRACT GmbH (Ilsenburg, acquired August 2017), a licensed manufacturer of liquid and freeze-dried sterile products, and is grouped under shared ownership with sister company Bendalis GmbH (oncology medicines, founded 2005). Adjacent R&D is conducted through research partnerships with University Hospital Tübingen, University Medical Centre Hamburg-Eppendorf and University Hospital Bremen, and Lyomark holds a strategic development partnership with Aerogen Pharma for an inhalable surfactant form of Alveofact.

Lyomark generates revenue through four streams: contract manufacturing (professional services), pharmaceutical active ingredient supply (transactional), direct product sales in Germany (own brands), and international licensing royalties and co-distribution arrangements with foreign partners. As a privately held, self-described "mittelständisches Unternehmen" (medium-sized enterprise) with leadership transitions completed in 2021–2022 — Dr. Wolfgang Burger (from PharmaZell) and Dr. Dirk Hütten — Lyomark positions itself as a GMP-compliant, partner-oriented specialty manufacturer and licensor for the sterile hospital segment, with no disclosed institutional or private equity ownership.

Lyomark Pharma firmographics

Firmographics
Name
Lyomark Pharma
Legal name
Lyomark Pharma GmbH
Website
https://lyomark.com
Company type
Private
Founded year
1989
Operating status
Operating
Headcount range
11–50 employees
Short description
Lyomark Pharma GmbH is a privately held German specialty pharmaceutical company (founded 1989, Oberhaching near Munich) that develops, manufactures and licenses sterile lyophilized and injectable products — notably Alveofact, NeoKay and NEOFACT — for the international hospital market, serving neonatology, gastroenterology and oncology customers via direct German sales and licensing partners in 50+ countries.
Ownership category
akta.pro rank

Lyomark Pharma industry classification

Industry
Product category
Sterile Hospital Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution

Keywords

  • Sterile pharmaceuticals manufacturing
  • Lyophilized injectable products
  • Neonatal lung surfactant
  • Contract pharmaceutical manufacturing
  • Hospital pharmaceutical supply

Where Lyomark Pharma is headquartered

Location

Headquarters

HQ city
Oberhaching
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Lyomark Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Manufacturing Services: Development of pharmaceutical formulations from pilot scale to commercial production, manufacture and packaging of lyophilised products and injectable solutions for pharmaceutical clients
  2. Pharmaceutical Active Ingredients Supply: Procurement of all active pharmaceutical ingredients and excipients, qualification of active pharmaceutical ingredient suppliers, GMP-compliant storage and on-time delivery
  3. Direct Product Sales (Germany): Direct sales of own products in the German hospital market since 2007, including Alveofact, NeoKay, and related pharmaceutical products
  4. International Licensing: International licensing and collaborations with distribution partners for worldwide distribution of Lyomark Pharma products, including co-distribution arrangements for selected products

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Lyomark Pharma product offering

Product offering

Core offering

Lyomark Pharma develops, manufactures, and distributes lyophilized (freeze-dried) and liquid sterile pharmaceutical products for the international hospital market. Its product portfolio is anchored in neonatology (Alveofact lung surfactant, NeoKay Vitamin K1 capsules, NEOFACT application aid), with additional specialty pharmaceuticals in gastroenterology and oncology. Beyond its own brands, the company offers contract manufacturing, regulatory dossier services (eCTD, PQR, PSUR), and active pharmaceutical ingredient supply to other pharmaceutical companies.

Product overview

Lyomark Pharma is a medium-sized pharmaceutical company specializing in sterile products for the hospital sector. The product portfolio centers on neonatology treatments including Alveofact® (bovine lung surfactant for respiratory distress syndrome), NEOFACT® (an innovative application aid for surfactant administration), and NeoKay® (Vitamin K1 prophylaxis). The company also provides contract manufacturing services for lyophilized and liquid sterile pharmaceuticals, pharmaceutical active ingredient procurement, regulatory services including PQR and PSUR creation, and international distribution partnerships. Products serve the hospital market across more than 50 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Alveofact: Lung surfactant product for neonatal respiratory conditions
  • NeoKay
  • NEOFACT

Products and services

  • Alveofact® Bovine lung surfactant derived from bovine lung lavage, used for the treatment of respiratory distress syndrome (RDS) in premature newborns. It contains phospholipids and surfactant proteins SP-B and SP-C and is supplied in 108 mg and 54 mg dosage forms.
  • NEOFACT® Application Aid Medical device / application aid that enables simple and gentle surfactant administration without Magill forceps, designed to standardize the less invasive LISA technique in neonatal intensive care.
  • NeoKay® 1 mg Soft Capsules Vitamin K1 (phytomenadione) prophylaxis in 1 mg soft capsule form for newborns and infants, used to prevent bleeding, particularly cerebral haemorrhage, due to vitamin K-dependent clotting factors.
  • Contract Manufacturing Services for Sterile Pharmaceuticals Pharmaceutical formulation development from pilot scale to validated commercial batch size, plus manufacture and packaging of lyophilized products (freeze-dried medicines) and injectable solutions for the international hospital market, executed under GMP for pharmaceutical clients.
  • Pharmaceutical Active Ingredients Supply Service Sourcing, qualification, and supply of active pharmaceutical ingredients and excipients including provision of CEP and EDMF documentation, GMP-compliant storage, and on-time delivery for pharmaceutical manufacturers.
  • Regulatory Services (eCTD, PQR, PSUR) Creation of Product Quality Reviews (PQR), Periodic Safety Update Reports (PSUR), and Regulatory Dossiers in eCTD format, together with database queries and ongoing support for approval processes for pharmaceutical clients.

Quantifiable outcome

  • NEOFACT showed 95% success rate in clinical feasibility study at University Hospital Tübingen
  • +1 more outcomes

Companies that use Lyomark Pharma

Customer profile

Segments3 records

Ideal customer profiles3 records

Lyomark Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Lyomark Pharma partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Aerogen PharmacoreStrategic or Co-development Partner · 14 December 2017Strategic partnership to develop an inhalable surfactant for the treatment of respiratory distress syndrome (RDS) in premature newborns, based on Lyomark's product Alveofact. Clinical studies were initiated with the new application form, with the first patients already recruited. The partnership aims to create a less invasive surfactant delivery method using Aerogen's aerosolized delivery technology.
  • LYOCONTRACT GmbHcoreStrategic or Co-development Partner · 1 August 2017Lyomark Pharma acquired a majority stake in LYOCONTRACT GmbH (based in Ilsenburg), which received its manufacturing licence in 2012 for production of liquid and freeze-dried sterile medicinal products. The plant was built to the latest standards and is among the most modern in its sector. Both companies remain privately owned and independently managed, with the goal of developing LYOCONTRACT into a leading contract manufacturer for sterile products.
  • Bendalis GmbHcoreStrategic or Co-development PartnerSister company founded in 2006, specializing in the development and marketing of high-quality oncology medicines for the treatment of cancer. Both companies are privately owned and work together under shared ownership.
  • University Hospital TübingenminorStrategic or Co-development PartnerClinical trial partnership for NEOFACT feasibility study conducted at University Hospital Tübingen, where 20 preterm infants were administered surfactant using the NEOFACT application aid with 95% success rate.
  • University Medical Centre Hamburg-EppendorfminorStrategic or Co-development PartnerResearch partnership with Dr. Julian Trah's research group studying immunomodulatory effects of surfactant products (Alveofact, Curosurf) on NET formation in neutrophil granulocytes.
  • University Hospital BremenminorStrategic or Co-development PartnerResearch partnership with Professor Dr. Dr. Ursula Mirastschijski investigating topical application of Alveofact for wound healing and scar formation, resulting in published Nature Magazine study.

Scale indicators3 records

Recent moves10 records

Expansion highlights5 records

Lyomark Pharma competitors and assessment

Company assessment

Broad incumbents

  • Recipharm: European CDMO offering sterile fill-finish and lyophilization services; comparable to Lyomark's contract manufacturing business for pharmaceutical clients across formulation, scale-up, and commercial production.
  • AbbVie: Global pharma incumbent with a historic neonatal surfactant franchise (Survanta) following the Abbott and Allergan acquisitions; broader respiratory and hospital portfolio overlaps with Lyomark's specialty hospital focus.
  • Aurobindo Pharma: Large global generics manufacturer with a substantial hospital sterile injectables business; a relevant comparability anchor for Lyomark's generic hospital injectables pipeline and international distribution model.
  • Curia Global: Global CDMO with sterile injectable manufacturing capabilities; competes for the same contract manufacturing and lyophilization work that Lyomark's LYOCONTRACT subsidiary targets.

Direct peers

  • B. Braun Melsungen: German-headquartered medical and pharmaceutical company with a large sterile injectables and hospital solutions portfolio; a closely comparable private German player in sterile hospital injectables.
  • Aenova Holding: German CDMO specializing in solid, semi-solid, and sterile liquid dosage forms; competes directly with Lyomark's contract manufacturing and lyophilization services for pharma clients.
  • Chiesi Farmaceutici: Privately held Italian specialty pharma with Curosurf (poractant alfa), the global market-leading lung surfactant for neonatal RDS — directly competing with Lyomark's Alveofact in the same indication and customer base.
  • Hikma Pharmaceuticals: Global manufacturer of generic injectable hospital products with a strong lyophilized injectables portfolio; directly comparable in hospital sterile injectables and contract manufacturing service offerings.

Regional players

  • Stada Arzneimittel: German specialty and generics pharma with strong hospital presence in Europe; comparable in offering hospital sterile injectables and specialty products, though at significantly larger scale.

Emerging players

  • Drägerwerk: German medical technology company with a strong neonatal care and respiratory product line (incubators, ventilators); comparable as a German specialty supplier into the same neonatal hospital customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Lyomark Pharma social profiles

Digital presence

Lyomark Pharma compliance and trust

Trust signal

Compliance3 records

Lyomark Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lyomark Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Lyomark Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Lyomark Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lyomark Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyomark Pharma

What does Lyomark Pharma do?

Lyomark Pharma develops, manufactures, and distributes lyophilized (freeze-dried) and liquid sterile pharmaceutical products for the international hospital market. Its product portfolio is anchored in neonatology (Alveofact lung surfactant, NeoKay Vitamin K1 capsules, NEOFACT application aid), with additional specialty pharmaceuticals in gastroenterology and oncology. Beyond its own brands, the company offers contract manufacturing, regulatory dossier services (eCTD, PQR, PSUR), and active pharmaceutical ingredient supply to other pharmaceutical companies.

Is Lyomark Pharma a public or private company?

Lyomark Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Lyomark Pharma founded?

Lyomark Pharma was founded in 1989. It employs 11 to 50 people.

Where is Lyomark Pharma based?

Lyomark Pharma is headquartered in Oberhaching, Germany, in the Europe region.

How does Lyomark Pharma make money?

Four revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are pharmaceutical Active Ingredients Supply, direct Product Sales (Germany) and international Licensing.

Who are Lyomark Pharma's main competitors?

Broad incumbents on record are Recipharm, AbbVie, Aurobindo Pharma and Curia Global. Direct peers are B. Braun Melsungen, Aenova Holding, Chiesi Farmaceutici and Hikma Pharmaceuticals. Stada Arzneimittel is listed as a regional player. Drägerwerk is listed as an emerging player.

Does Lyomark Pharma have an API?

No public API is recorded for Lyomark Pharma.

What industry is Lyomark Pharma in?

Lyomark Pharma's product category is Sterile Hospital Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals